MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma by Olasz, Edit B. et al.
                                                              
University of Dundee
MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous
Squamous Cell Carcinoma
Olasz, Edit B.; Seline, Lauren N.; Schock, Ashley M.; Duncan, Nathan E.; Lopez, Argelia;
Lazar, Jozef; Flister, Michael J.; Lu, Yan; Liu, Pengyuan; Sokumbi, Olayemi; Harwood,
Catherine A.; Proby, Charlotte M.; Neuburg, Marcy; Lazarova, Zelmira
Published in:
PLoS ONE
DOI:
10.1371/journal.pone.0125412
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Olasz, E. B., Seline, L. N., Schock, A. M., Duncan, N. E., Lopez, A., Lazar, J., ... Lazarova, Z. (2015). MicroRNA-
135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma. PLoS ONE,
10(5), 1-16. [e0125412]. DOI: 10.1371/journal.pone.0125412
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
RESEARCH ARTICLE
MicroRNA-135b Regulates Leucine Zipper
Tumor Suppressor 1 in Cutaneous Squamous
Cell Carcinoma
Edit B. Olasz1, Lauren N. Seline1, Ashley M. Schock1, Nathan E. Duncan1, Argelia Lopez1,
Jozef Lazar1, Michael J. Flister2, Yan Lu2, Pengyuan Liu2, Olayemi Sokumbi1, Catherine
A. Harwood3, Charlotte M. Proby4, Marcy Neuburg1, Zelmira Lazarova1*
1 Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of
America, 2 Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United
States of America, 3 Centre for Cutaneous Research, Blizard Institute, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 4 Division of Cancer
Research, Medical Research Institute, Ninewells Hospital & Medical School, University of Dundee,
Dundee, United Kingdom
* zlazarov@mcw.edu
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy
and it presents a therapeutic challenge in organ transplant recipient patients. Despite the
need, there are only a few targeted drug treatment options. Recent studies have revealed a
pivotal role played by microRNAs (miRNAs) in multiple cancers, but only a few studies test-
ed their function in cSCC. Here, we analyzed differential expression of 88 cancer related
miRNAs in 43 study participants with cSCC; 32 immunocompetent, 11 OTR patients, and
15 non-lesional skin samples by microarray analysis. Of the examined miRNAs, miR-135b
was the most upregulated (13.3-fold, 21.5-fold; p=0.0001) in both patient groups. Similarly,
the miR-135b expression was also upregulated in three cSCC cell lines when evaluated by
quantitative real-time PCR. In functional studies, inhibition of miR-135b by specific anti-miR
oligonucleotides resulted in upregulation of its target gene LZTS1 mRNA and protein levels
and led to decreased cell motility and invasion of both primary and metastatic cSCC cell
lines. In contrast, miR-135b overexpression by synthetic miR-135b mimic induced further
down-regulation of LZTS1 mRNA in vitro and increased cancer cell motility and invasive-
ness. Immunohistochemical evaluation of 67 cSCC tumor tissues demonstrated that miR-
135b expression inversely correlated with LZTS1 staining intensity and the tumor grade.
These results indicate that miR-135b functions as an oncogene in cSCC and provide new
understanding into its pathological role in cSCC progression and invasiveness.
Introduction
Cutaneous squamous cell carcinoma (cSCC) is the second most common human skin cancer,
and it is reported to be within the top five most costly cancers in the US Medicare population
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[1]. Uncomplicated sporadic cSCCs are typically curable by surgery or a combination of sur-
gery, topical chemotherapy, and radiotherapy. The clinical problem of cSCC is especially severe
in immunocompromised individuals such as solid-organ transplant recipients (OTR). These
patients have 65 to 250 times the normal incidence of cSCC and more importantly a signifi-
cantly higher risk of metastasis [2]. Metastatic cSCC present a significant therapeutic problems
since chemotherapy is not consistently efficient [3]. In addition, prognosis for OTR patients
with cSCC is extremely poor, with an overall survival rate at 1 year of 44–56% [3]. Thus, there
is a great need to identify specific molecules involved in cSCC invasion and metastasis which
can potentially serve as target for new treatment strategies.
MicroRNAs (miRNAs) are small non-coding RNA molecules capable of regulating gene ex-
pression at the post-transcriptional level [4]. They can repress translation or induce mRNA
cleavage by binding to the 3’ untranslated region of target mRNA [5, 6]. Alteration of miRNA
expression has emerged as one of the key features in cancer-associated dysfunction of gene reg-
ulatory networks. Until recently only few studies have evaluated the miRNA expression in
cSCC [7–11]. A previous microarray analysis of miRNA from immunocompetent (IC) cSCC
patient-matched samples revealed changed expression of 9 miRNAs in cSCC tissues, of which
miR-135b showed the largest change (upregulated 8.5-fold) between cancerous and paired nor-
mal tissues [8].
miR-135b has been implicated in cancer growth [12], survival [13], motility [14], and inva-
siveness [15] and has been shown to be upregulated in multiple other tumor types (i.e., breast,
lung, colon, and prostate) [13, 15–17]. Interestingly, miR-135b function has been described as
an oncogenic [14–16] or tumor-suppressive [18] in malignant tumors originated from different
tissues. In head and neck SCC miR-135b was described as a tumor promoter by stimulating
cancer cell proliferation, colony formation, and angiogenesis through activation of HIF-1α
[19]. However, despite miR-135b being upregulated in cSCC, the function of this miRNA in
the cSCC progression has not been investigated.
The leucine zipper tumor suppressor 1 (LZTS1) gene was described as the tumor suppressor
gene by Ishii at all in 1999 [20]. Functional studies demonstrated that deletion of one or both
alleles of LZTS1 gene in mouse results in onset of spontaneous tumors in several organs includ-
ing skin [21] and reintroduction of LZTS1 gene suppresses tumorigenicity in nude mice in vivo
[22]. Recently LZTS1 has been identified as a target-gene of miR-135b [15] and has been impli-
cated in tumor growth [23], motility [24], and invasiveness [22] in multiple tumors. However,
the role of LZTS1 in cSCC progression and the clinical implication between miR-135b expres-
sion, LZTS1 expression and histological tumor grade has not yet been tested.
In this study we tested the expression of miR-135b and LZTS1 in cSCC tumor tissues ob-
tained from IC and OTR patients and cSCC cell lines. Keratinocyte cell lines spontaneously de-
rived from human skin are rare and published cSCC lines usually represent a late stage of
malignant transformation [25]. To evaluate the miR-135b regulation of LZTS1 expression in
vitro we have used three cSCC cell lines derived from an immunosuppressed renal transplant
(OTR) patient described and characterized previously [26, 27]. These unique cell lines repre-
sent early and advanced stages of malignant transformation of the epidermis starting from dys-
plastic (PM1), to primary tumor (MET1), and metastatic tumor (MET4) and provide a tool for
evaluation of microRNA expression at the different stage of disease progression in vitro. Using
multiple gain-of-function and loss-of-function assays, we describe for the first time that LZTS1
is indeed a target gene of miR-135b in cSCC and mirR-135b expression inversely correlates
with staining intensity of LZTS1and tumor grade in cSCC tumor samples. In addition, inhibi-
tion of miR-135b blocks cSCC cell motility and invasiveness without inhibition of cell prolifer-
ation. Collectively, our data demonstrate that miR-135b plays an oncogenic role in cSCC
through downregulation of tumor suppressor gene LZTS1and may potentially serve as a
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molecular target for therapeutic interventions in OTR patients with multiple or difficult to
manage tumors.
Materials and Methods
Clinical samples
Tissue samples were taken after obtaining written informed consent from cSCC patients un-
dergoing Mohs-micrographic surgery at the Skin Cancer Center, Froedtert Hospital and Medi-
cal College of Wisconsin, Milwaukee. This study was approved by the Medical College of
Wisconsin Institutional Review Board and in accordance with the Declaration of Helsinki
Principles (Institutional Review Board Assurance of Compliance Number for this study:
FWA00000820). The clinical diagnosis of cSCC was made by the Mohs-surgeon and tumor
grade and LZTS1 staining intensity was evaluated and confirmed by dermatopathologists.
Tumor tissue was obtained from 134 patients as follows: A) 32 IC patients, 11 OTRs patients
(total n = 43), 15 non-lesional skin samples for miRNA microarray studies. B) 42 paraffin-em-
bedded and 25 OCT-embedded tumor samples for immunohistochemistry studies.
Cancer cell lines
The human cSCC cell lines MET1 and MET4 were derived from a single renal transplant recip-
ient (OTR) patient who suffered from multiple cSCCs. MET1 was derived from a primary inva-
sive cSCC tumor and MET4 from an associated lymph node metastasis [26]. The PM1
keratinocyte cell line was cloned from cultures of dysplastic forehead skin of the same patient
that showed an extended life span in vitro. These cell lines represent the first sequential series
of cSCC from the same patient that can be used as a model to study the course of epigenetic
regulations in vitro [26]. All cell lines were thawed from frozen stocks, cultured in a nutrient
mix of Dulbecco’s minimal essential medium with Ham’s F12 medium (3:1) supplemented
with hydrocortisone, human insulin, cholera toxin, Apo-transferrin, lyothyronine (L4), and an-
tibiotics/antimycotics in a 37°C incubator at 5% CO2.
Real-time PCR array analysis of miRNA expression
Total RNA, including miRNA, was isolated with themirVana miRNA Isolation Kit (Life Tech-
nologies, Grand Island, NY) from all tumor and control non-lesional skin samples. The RNA
concentration and purity were determined using the NanoDrop ND-2000 spectrophotometer
(Thermo Fisher Scientific, Waltman, USA). Tissue samples were analyzed for the presence and
differential expression of a panel of 88 cancer-related miRNAs using a human cancer specific RT2
miRNA PCR array (SABiosciences) according to the manufacturer's instructions. The miRNA ex-
pression was normalized to four housekeeping genes (SNORD48, SNORD47, SNORD44, RNU6-
2) and then tumor miRNA levels were compared with those in non-lesional skin samples using
manufacturer's software. Resulting miRNA expression data was submitted to the ArrayExpress
database (http://www.ebi.ac.uk/arrayexpress/) with the accession number of E-MTAB-3409.
Transfections assay
Cells were transfected with 10nM ofmirVana inhibitor or 15nM ofmirVana mimic to miR-135b
(Life Technologies) using Lipofectamine RNAiMAX (Life Technologies) according to the manu-
facturer’s protocol. For each set of cells a correspondingmirVana negative control for the inhibi-
tor or mimic was used. qRT-PCR analysis of LZTS1 mRNA expression in the transfected cells
was performed with High Capacity RNA-to-cDNA Kit (Life Technologies) and Power SYBR
Green Master Mix (Life Technologies). Primers used for qRT-PCR amplification of human
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LZTS1 gene were as follows; Fwd 5’-ACCTCTAGAAACCCAGAACTCA-3’, Rev 5’-TCCA
GAAGAGCCCATATCACTA-3’. The results were normalized to the levels of the housekeeping
gene GAPDH; Fwd 5’-GCGCCCAATACGACCAA-3’, Rev 5’-CTCTCTGCTCCTCCTGTTC-
3’. Gene transcripts were amplified by qRT-PCR using the Applied Biosystems StepOnePlus cy-
cler. Thermal cycler conditions were as follows: 2 minute UNG incubation at 50°C and 10 minute
polymerase activation at 95°C followed by forty cycles of 95°C for 15 sec and 60°C for 1 minute.
Migration assay
To evaluate cSCC cell line motility, transfected cells were first grown to confluency. The mono-
layer was scratched in a standard manner using a 200 μl sterile pipette tip to create a cell-free
zone. The medium was aspirated and replaced with fresh complete medium then the cells were
incubated for 24 hours at 37°C. In vitromigration was documented at 24 hours by photogra-
phy. The assay was performed in triplicate for each experimental condition. The residual gaps
between the migrating keratinocytes were measured at five random intervals for each experi-
mental condition and then expressed as a percentage of the original scratch width using NIH
Image J program 1.48b.
Transwell invasion assay
The invasion assay was performed using a 24-well BD BioCoat Invasion Chamber (BD Biosci-
ences, USA). Cells transfected with 10nM ofmirVana inhibitor or 15nM ofmirVana mimic to
miR-135b and appropriate controls were harvested 24 hours after transfection. The cells were
re-suspended in a serum free media with reduced growth factors (as previously stated) and
added to the upper chamber at a density of 1x104 cells per well in triplicate; the bottom cham-
ber contained growth media supplemented with 10% fetal bovine serum (FBS) and normal
concentration of growth factors. After incubating for 24 hours, cells in the upper well were re-
moved by aspiration of the Matrigel and wiping the top of the membrane with a cotton swab.
Cells on the underside of the membrane were fixed using the Differential Quik Stain Kit (Poly-
sciences, Inc., USA). Briefly, the membranes were submerged sequentially in each solution (A,
B, and C) for 2 minutes, then rinsed twice in deionized water and allowed to air dry. Invading
cells were evaluated using images of five microscopic fields per membrane under light micros-
copy at a magnification of 40x. The number of invading cells in each photograph were then
counted using NIH Image J program 1.48b.
Proliferation assay
To monitor cell proliferation of PM1, MET1, MET4 cell lines, 5000 cells/well were seeded in
96-well microplate in a final volume of 100ul. For proliferation assays we used the CyQUANT
NF Cell proliferation Assay Kit (Invitrogen, USA) constructed on measurement of cellular
DNA content via fluorescent dye binding. Briefly, the cells transfected with 10nM ofmirVana
inhibitor or 15nM ofmirVana mimic to miR-135b and appropriate controls were incubated
with CyQUANT NF reagent for 60 minutes at 37°. Fluorescence intensities were measured
with a microplate reader using excitation at 485 and fluorescence detection at 530 nm at indi-
cated time points according to manufacturer’s protocol. Each data point was obtained as an av-
erage of triplicate samples.
Immunohistochemistry and immunocytochemistry
The LZTS1 protein expression was evaluated by immunohistochemistry on (n = 67) cSCC tu-
mors. Twenty five tumor samples were embedded in OCT compound and processed by
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immunofluorescence studies, and forty two tumor samples were evaluated from paraffin em-
bedded tissues. Frozen OCT-embedded 6-μm-thick sections of cSCC were fixed for 10 minutes
in 10% neutral buffered formalin then washed twice with phosphate buffered saline solution
(PBS). Slides were blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour at room
temperature, then incubated with rabbit polyclonal antibody to LZTS1 (Novus Biologicals,
USA) at a dilution of 1:200 for 1 hour at room temperature. Normal rabbit IgG at the same di-
lution served as a negative control. Following aspiration of the primary antibody and two
washes in PBS, LZTS1 was detected by affinity-purified, Alexa Fluor 488 donkey anti-rabbit
IgG (H+L) (Invitrogen, USA) at a dilution of 1:100 for 30 minutes. Slides were then washed
and stained with DAPI (MP Biomedicals, USA) at a dilution of 1:1000 for one minute. At the
end of the procedure, slides were washed, cover slipped, coded and evaluated under a fluores-
cent microscope. LZTS1 fluorescence staining intensity in the OCT-embedded tumor and
non-lesional epidermis and in transfected cSCC cell lines was evaluated using images of five
microscopic fields per slide at a magnification of 200x. Mean fluorescence intensity in five stan-
dardized areas of tumor and non-involved epidermis for each optical field were measured and
the intensity of fluorescence staining was evaluated using the NIH Image J program 1.48b. The
LZTS1 staining intensity in the cells transfected with miR-135b mimic or miR-135b inhibitor
was evaluated after fixation of cells for 2 minutes with 95% ethanol in the same manner as the
OCT-embedded tumor samples.
The paraffin-embedded tumor samples (n = 42) were deparaffinized and antigen retrieval
was performed with Vector Antigen Unmasking Solution (Dako North America, Inc., USA).
Slides were then blocked with 1% BSA in PBS plus 0.03% tween for 1 hour. Next, slides were
stained using primary LZTS1 specific rabbit polyclonal antibody at 1:200 dilution overnight at
4°C. The Dako Envision system-HRP Kit was then used for the secondary HRP-labeled anti-
rabbit IgG for 30 minutes at room temperature and developed with Chromogen Substrate
(Dako Envision System-HRP kit). The slides were counterstained with hematoxylin (Vector
Laboratories Inc., USA). The histological tumor grade was established by dermatopathologist
using hematoxylin and eosin stained tumor sections as described previously [28]. The LZTS1
staining intensity was quantified in the paraffin-embedded tumor and non-lesional epidermis
by dermatopathologist using semiquantitative grading scale where 0 represented absence of
staining, 1 = light staining, 2 = moderate staining, and 3 = dark staining typically seen in the
uninvolved normal epidermis which served as an internal control for each slide.
Statistical analysis
For the microarray evaluation, the expression of miRNAs for all tumor samples was first nor-
malized to four housekeeping genes and then compared with those in non-lesional skin sam-
ples. To assess the differences between the groups, nonparametric permutation tests were
performed to calculate the p-value for each miRNA. False discovery rate was controlled for
multiple testing [29]. The p-value of permutation less than 0.003 was considered statistically
significant. To test the strength of the relationship between the tumor grade and LZTS1 stain-
ing intensity we used Spearman’s Rank correlation. For the remaining experiments the
statistical analysis was performed using the Student t test. The data were expressed as
mean ± standard deviation, the significance level was p<0.05.
Results
MicroRNA expression signatures in cSCC tissues
To test miRNA expression in cSCC, miRNA transcripts were isolated from cSCC samples of 32
IC patients, 11 OTRs patients (total n = 43), and control non-lesional skin samples (n = 15) and
miR-135b Regulates LZTS1 in Cutaneous Squamous Cell Carcinoma
PLOSONE | DOI:10.1371/journal.pone.0125412 May 4, 2015 5 / 16
analyzed by qRT-PCRmiRNA array. Compared with control samples, 4 miRNAs (miR-135b,
miR-142-5p, miR-181a, and miR-18a) were significantly upregulated in cSCC from IC patients,
whereas 16 were significantly downregulated in IC cSCC samples (Table 1). TwomiRNA were
significantly upregulated (miR-135b and miR-181a) and 17 were downregulated in cSCC sam-
ples from OTR patients (Table 2). Overall, we observed concordant changes in 11 of 26 differen-
tially expressed genes between cSCC samples from IC and OTR patients. Of these genes, miR-
135b had the largest difference in cSCC samples from OTR patients (21.5-fold; p<0.0001) and
IC patients (13.3-fold; p<0.0001) compared with non-lesional controls (Fig 1A and 1B).
LZTS1 expression is down-regulated in cSCC tissues and cell lines
LZTS1 has recently been identified as a miR-135b target-gene in non-small-cell lung carcinoma
that significantly correlates with patient survival [15]. In addition, down-regulation of LZTS1
is associated with poor prognosis in human breast carcinoma [24]. We hypothesized that miR-
135b could also regulate LZTS1 expression in cSCC. To test this possibility, we first examined
expression of LZTS1 protein expression by immunohistochemistry in cSCC (n = 25; 2 OTRs
and 23 IC) and normal uninvolved skin matched samples. In normal skin, LZTS1 staining lo-
calized strongly to the basal and suprabasal layers with a mean fluorescent intensity (MFI) of
11.6± 5.6 (Fig 2A). In comparison, LZTS1 staining was markedly diminished in cSCC tumors
(4.3 ± 3.1 MFI; p<0.001) (Fig 2A and 2B). LZTS1 staining intensity was also diminished in the
42 (8 OTRs and 34 IC) paraffin-embedded tumor samples (71.02 ± 36.5) when compared to
non-lesional skin (227.5 ± 8.3; p<0.001) (Fig 2C and 2D). Importantly, the more invasive and
less differentiated tumors (grades 3 and 4) had significantly lower LZTS1 staining intensity (r =
-0.51, p<0.00058) then non-invasive or well differentiated tumors (grades 1 and 2); as estimat-
ed by Spearman’s rank correlation. No significant correlation was observed in LZST1 staining
Table 1. Statistical analysis of differentially expressed miRNAs in cSCC tissues from immunocompe-
tent patients.
miRNA ID p-value of Permutation Fold Change
hsa-miR-135b 0.0001 13.344
hsa-miR-142-5p 0.0001 6.41
hsa-miR-181a 0.0003 2.98
hsa-miR-18a 0.0009 2.162
hsa-miR-215 0.0024 -7.723
hsa-miR-10b 0.0028 -5.6
hsa-miR-125b 0.0001 -5.596
hsa-miR-200c 0.0001 -4.934
hsa-miR-10a 0.001 -4.605
hsa-miR-191 0.0001 -4.413
hsa-miR-25 0.0017 -4.368
hsa-miR-203 0.0003 -3.816
hsa-miR-183 0.0035 -3.659
hsa-miR-100 0.0001 -3.623
hsa-miR-149 0.0013 -3.51
hsa-miR-15b 0.0001 -3.408
hsa-let-7c 0.0009 -3.397
hsa-miR-23b 0.0001 -3.234
hsa-miR-193a-5p 0.0012 -2.988
hsa-let-7b 0.002 -2.925
doi:10.1371/journal.pone.0125412.t001
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Table 2. Statistical analysis of differentially expressedmiRNAs in cSCC tissues from organ transplant
recipients.
miRNA ID p-value of Permutation Fold Change
hsa-miR-135b 0.0001 21.496
hsa-miR-181a 0.0005 5.005
hsa-miR-25 0.0001 -8.447
hsa-miR-125b 0.0001 -7.445
hsa-miR-215 0.0032 -6.899
hsa-miR-10a 0.0003 -5.118
hsa-miR-10b 0.0011 -5.053
hsa-miR-191 0.0001 -4.849
hsa-miR-200c 0.0001 -4.757
hsa-miR-203 0.0001 -4.423
hsa-miR-100 0.0001 -4.21
hsa-miR-9 0.0027 -3.971
hsa-miR-23b 0.0001 -3.637
hsa-miR-15b 0.0001 -3.594
hsa-miR-92a 0.0035 -3.228
hsa-miR-16 0.001 -3.112
hsa-miR-125a-5p 0.0017 -2.657
hsa-miR-218 0.0023 -2.611
hsa-miR-128a 0.0032 -1.963
doi:10.1371/journal.pone.0125412.t002
Fig 1. Differentially expressedmiRNAs in human cSCC tissue. A) PCR array analysis of miRNA
expression in cSCC tumors from immunocompetent patients (n = 32). B) PCR array analysis miRNA
expression in cSCC tumors from organ transplant recipients (n = 11).
doi:10.1371/journal.pone.0125412.g001
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intensity and tumor grade between OTRs and IC samples. We detected reduced LZTS1 stain-
ing intensity in the tumor samples from OTRs. However, due to the low number of OTRs sam-
ples this trend did not reach statistical significance. Next we assessed miR-135b and LZTS1
expression in 3 human primary and metastatic cSCC cell lines by quantitative qRT-PCR. Ex-
pression of miR-135b was compared to the baseline expression in PM1 cells and RNU6B was
used as a normalization control. Compared with PM1, miR-135b expression was significantly
elevated in the primary invasive MET1 (24.4 ±2.3-fold; p<0.01) and metastatic MET4
(32.5 ± 8.9-fold; p<0.01) cell lines (Fig 3A). In line with our previous findings on the tumor tis-
sues, the miR-135b expression was higher in the metastatic cell line (MET4) than in the prima-
ry invasive (MET1) cell line. Taken together, these data suggest an association between LZTS1
and miR-135b expression in cSCC.
miR-135b regulates LZTS1 expression in cSCC cell lines
To directly test whether miR-135b regulates LZTS1 expression in cSCC in vitro, the PM1,
MET1, and MET4 cell lines were transfected with syntheticmirVana miR-135b inhibitor,
Fig 2. Immunohistochemical analysis of LZTS1 protein levels in normal human skin and cSCC tissues. A, C) LZTS1 staining is localized in the normal
epidermis, but is largely absent in the tumor tissue. Arrows point towards the tumor nests. The absence of staining with control rabbit IgG antibody confirms
the specificity of LZTS1 antibody. B, D) Evaluation of LZTS1 staining intensity shows significant reduction of LZTS1 staining in the tumor tissue when
compared to normal non-lesional epidermis. * indicate p values less than 0.001. Bar = 100um.
doi:10.1371/journal.pone.0125412.g002
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mirVana miR-135b mimic, ormirVana negative control and tested in functional assays. At 48
hours post-transfection LZTS1 expression was assessed by qRT-PCR, and quantitative immuno-
fluorescent staining of the cSCC cell lines. Compared with the negative control, the miR-135b in-
hibitor significantly increased LZTS1 mRNA expression in PM1 (2.1 ± 0.7-fold; p< 0.05),
MET1 (4.0 ± 1.2-fold; p< 0.05), and to a lesser extent in MET4 (1.5 ± 0.5-fold) (Fig 3B). Similar
to changes in LZTS1 mRNA transcript expression, LZTS1 staining intensity was significantly in-
creased in PM1 (3.34 ± 2.0-fold; p<0.001) andMET1 (1.7 ± 0.7-fold; p<0.001) cells treated with
the miR-135b inhibitor, whereas LZTS1 staining intensity in MET4 did not change (Fig 4A and
4B). In contrast, all cSCC cell lines transfected with miR-135b mimics (to increase endogenous
miR-135b expression) demonstrated further downregulation of LZTS1 (PM1–1.00 ± 0.11-fold;
MET1–1.60 ± 0.15-fold; MET4–1.77 ± 0.07-fold) within 24 hours post-transfection when com-
pared to the negative control as shown in Fig 5A and 5B. Collectively, these data demonstrate
that LZTS1 expression is regulated by miR-135b in cSCC cells in vitro.
Fig 3. Functional assays of miR-135b inhibition and overexpression. A) Baseline mRNAmiR-135b expression in 3 different OTR-derived cSCC cell
lines was established by qRT-PCR. B) Effect of miR-135b inhibition on LZTS1mRNA expression in cSCC lines by qRT-PCRwithin 48 hours post-
transfection. C) Effect of miR-135b overexpression on LZTS1mRNA expression in cSCC lines by qRT-PCRwithin 48 hours post-transfection. * indicate p
values less than 0.005.
doi:10.1371/journal.pone.0125412.g003
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Fig 4. Immunohistochemical analysis of LZTS1 protein levels in cells transfected with miR-135b inhibitor. A) cSCC cell lines transfected with miR-
135b inhibitor showed increased LZTS1staining intensity 48 hours post-transfection when compared to negative control. B) Mean fluorescent intensity per
cell was quantified using NIH image J program in cell transfected with miR-135b inhibitor and negative control oligonucleotiides. * indicates p values less
than 0.001. Bar = 1000um.
doi:10.1371/journal.pone.0125412.g004
Fig 5. Immunohistochemical analysis of LZTS1 protein levels in cells transfected with miR-135bmimic. A) All cSCC cell lines transfected with miR-
135b mimic showed decreased LZTS1staining intensity 48 hours post-transfection when compared to negative control. B) Mean fluorescent intensity per cell
was quantified using NIH image J program in cell transfected with miR-135b mimic and negative control oligonucleotiides. * indicates p values less than
0.001. Bar = 1000um.
doi:10.1371/journal.pone.0125412.g005
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miR-135b affects cSCCmigration and invasion
Since LZTS1 has been reported as a biomarker of poor clinical outcome in other tumor types
[24, 30–32], we hypothesized that miR-135b could influence the metastatic invasiveness of
cSCC by modulating LZTS1expression. To test this hypothesis, we examined the effects of
miR-135b inhibition on cSCC cell migration and invasion, two key components of malignant
tumor progression [33]. As shown in Fig 6A and 6B, treatment with miR-135b inhibitor signif-
icantly suppressed motility of all PM1 (29 ± 8%; p<0.001), MET1 (30 ± 16%; p<0.001), and
MET4 (39 ± 9%; p<0.001) cell lines in a wound scratch assay compared with the negative con-
trol. Next we assessed the effect of miR-135b inhibition on cell invasion. Interestingly, miR-
135b inhibition reduced cSCC invasion by 2.2-fold (p<0.01) in PM1 and by 2.4-fold (p<0.01)
in MET1 cells when compared with the negative control (Fig 6C and 6D). The MET4 (meta-
static) cell line invasive capacity was not affected by miR-135b inhibition. In contrast,
miR-135b overexpression by synthetic miR-135b mimic further increased cancer cell motility
(Fig 7A and 7B) and invasiveness (Fig 7C and 7D). These data indicate that miR-135b can reg-
ulate cell migration and tumor invasiveness in early stages of cSCC progression and can act as
an oncogenic miRNA in human keratinocytes.
Fig 6. miR-135b inhibition delays cell migration and invasion in MET1, PM1 andMET4 cSCC cell lines. A, B) miR-135b inhibitor significantly delays
cSCC cell migration in the wound scratch assay within 24 hours post-transfection. C, D) miR-135b inhibitor significantly reduces cSCC cell invasion in the
Matrigel transwell invasion assay. * indicate p values less than 0.01. A) Bar = 100um; B) Bar = 200um.
doi:10.1371/journal.pone.0125412.g006
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Inhibition of miR-135b does not affect the cSCC proliferation
To determine if miR-135b affects the proliferative potential of cSCC cells, we performed prolif-
eration assay on all three cSCC cell lines transfected with miR-135b inhibitor. Interestingly,
none of the tested cSCC cell lines showed decreased proliferation capacity after the miR-135b
inhibition when compared to negative control transfected cells as shown in Fig 8. Collectively
these data indicate that inhibition of miR-135b blocks cSCC cell motility and invasiveness
without inhibition of tumor cell proliferation, thus implicating involvement of additional path-
ways supporting the tumor growth.
Discussion
The risk of developing cSCC is markedly increased in OTRs compared to the normal popula-
tion. The sun exposure and the immunosuppressive regimen are important risk factors for the
development of cSCC in OTRs. Recent studies suggest that some miRNAs are critical not only
in promoting successful transplant outcomes after both solid organ and hematopoietic stem
cell transplantation [34, 35], but can play an important role in tumor progression and metasta-
sis. A genome-wide sequencing study demonstrated vast differences in gene expression profiles
Fig 7. miR-135b overexpression increases cell migration and invasion in MET1, PM1 and MET4 cSCC cell lines. A, B) miR-135b mimic significantly
increases cSCC cell migration in the wound scratch assay within 24 hours post-transfection. C, D) miR-135b mimic significantly increases cSCC cell invasion
in the Matrigel transwell invasion assay in PM1 cell line. * indicate p values less than 0.01. A) Bar = 100um; B) Bar = 200um.
doi:10.1371/journal.pone.0125412.g007
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between cSCC, actinic keratoses and normal skin from immunosuppressed OTRs thus bring-
ing to attention other molecular mechanisms such as miRNA alterations which may affect
gene expression in this group of patients [36]. MiR-135b has been implicated in tumor progres-
sion of multiple cancer-types [14, 15, 37], but the status of miR-135b in cSCC from IC and
OTRs and its functional role in either type of cSCC are currently unknown. Here, we demon-
strated that miR-135b was the most elevated miRNA in cSCC tissues from both IC and OTR
patients (Table 1A and 1B). There are several genes regulated by miR-135b, among them, a
tumor suppressor gene, LZTS1 that was recently shown to be a miR-135b target-gene in multi-
ple cancers, [15, 30, 31, 38], but had not been tested in cSCC. We found that inhibiting miR-
135b in cSCC OTR-derived cell lines resulted in increased expression of LZTS1 transcript and
protein levels (Figs 4 and 5). The resulting increase in LZTS1 levels suppressed cSCC cell mi-
gration (Fig 6A and 6B) and invasion (Fig 6C and 6D) without affecting cell proliferation, dem-
onstrating that miR-135b is an oncomir that functions via downregulation of the LZTS1
tumor-suppressor gene. We also demonstrated that overexpression of endogenous miR-135b
in all three cSCC cell lines using specific miR-135b mimic further downregulated the mRNA
LZTS1 expression and increased tumor cell motility and invasion.
In our study the mRNA levels of miR-135b correlated with malignant cell phenotype. The
metastatic cell line (MET4) had higher endogenous miR-135b expression level when compared
to a cSCC cell line derived from dysplastic skin or primary tumor suggesting, that miR-135b
may be one of the regulating factors in the tumor progression. Similarly, studies in colon cancer
have demonstrated an increase in expression of miR-135b in both adenomas and carcinomas
Fig 8. miR-135b does not affect the cSCC cell proliferation in vitro. Proliferation of cSCC cells
transfected with miR-135b inhibitor versus negative control oligonucleotides. Each data point was obtained
as an average of triplicate samples. P value from two-sided Student's t test compares the measurement of
cellular DNA content via fluorescent dye binding between the two groups. p value greater than 0.05 was
calculated for all three cell lines at all individual time points.
doi:10.1371/journal.pone.0125412.g008
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compared to normal epithelium [39]. The progressive increase in miR-135b expression from
normal to polyp to carcinomatous tissues suggested that miR-135b dysregulation is an early
event that is amplified with increasing dysplasia [13]. Thus data from our study suggest that
miR-135b might similarly influence cSCC progression through modulation of tumor suppres-
sors, such as LZTS1.
LZTS1 is a tumor suppressor gene [30, 31, 38] that is regulated by miR-135b in lung cancer
[15], but the relationship and functional roles of the miR-135b/LZTS1 axis in cSCC were un-
known. We found that LZTS1 expression was strongly downregulated in cSCC tumors com-
pared with ubiquitous LZTS1 expression in normal epidermis (Fig 3). This fits with previous
reports of decreased LZTS1 expression in multiple other tumor types e.g., lung, breast, prostate
and kidney carcinomas [15, 23, 30–32, 40], in which LZTS1 levels were negatively correlated
with tumor progression [24]. However, we did not find a significant correlation between
LZST1 staining intensity and tumor grade in OTRs versus IC samples, presumably due to the
low number of tumor samples from OTRs. We found that LZTS1 levels negatively correlated
with miR-135b expression and malignant phenotype of cSCC cell lines (Fig 4). Importantly,
miR-135b blockade increased LZTS1 expression resulting in decreased cSCC motility and inva-
sion (Fig 7).
It has been shown that human tumor suppressor genes often function as negative regulators
of the cell cycle. The down regulation of LZTS1 by upregulated miR-135b can lead to failure of
cell cycle machinery in M-phase resulting in accumulation of genetic changes which often
leads to genetic instability and aneuploidy [41]. This concept is in line with the fact that mice
knockout for LZTS1develop a wide variety of tumors suggesting that aneuploidy phenotype
could drive cellular transformation in vivo [21, 42]. Interestingly, our data demonstrate that in-
hibition of miR-135b does not affect proliferative capacity of cSCC in vitro indicating that loss
of miR-135b while affecting the malignant cell migration and invasive functions, does not con-
tributes to the tumor growth. In line with our results, in a recently published study Wu et al
[43] describe regulation of metastasis suppressor-1 (MTSS1) by miR-135b in the colorectal
cancer. MTSS1 may exert its function by acting as a scaffold protein that interacts with actin-
associated proteins thus affecting lamellipodium formation and cell motility without affecting
cell proliferation capacity.
Collectively, these data suggest that the miR-135b/LZTS1 signaling axis plays an important
role in cSCC progression and suggests that miR-135b might be useful therapeutic target for
cSCC not only in IC but in OTR patients. Further studies using the miR-135b interference
strategy will be needed to develop new treatment modalities for this common human cancer.
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